Aggregated public profile · Not an official account.

The author reported that a study conducted by Memorial Sloan Kettering in New York on nearly 40,000 patients found hereditary genetic alterations in 8-18% of cancer patients, depending on the age at diagnosis. He questioned whether it would be appropriate to sequence the DNA of everyone. #Cancro #Genetica #SequenziamentoDNA #US (translated)

The author wrote that today eight out of ten children recover from cancer, but the two who do not make it are still "two too many." He added that in the last 20 years scientific research in this field has made great progress and will continue to advance. https://t.co/kBqPdO5C1M #Cancro #Salute #ProgressoScientifico #IT (translated)

The author wrote that the goal remained to beat cancer against time and that artificial intelligence could be an important ally, provided that it is used correctly. He added that it should not become a privilege for a few, but a global standard, and he presented its spread as a matter of when, not if. (translated)

The author wrote that the technologies in question did not belong to a science fiction future: he said he was personally working on them and that they were gradually entering the research laboratories and multidisciplinary oncology committees of many institutions around the world. (translated)

The author wrote that artificial intelligence models could identify complex patterns not detectable by the human eye or traditional software. He added that by integrating genomic, imaging, and clinical data, AI could identify who would respond to a specific therapy and pinpoint a response marker. (translated)

The author wrote that, in his opinion, artificial intelligence could contribute to the development of new oncological therapies and potentially make the work of oncologists simpler. He added that he would illustrate three main functions in a thread, specifying that they were not necessarily the only ones. #IntelligenzaArtificiale #Oncologia #TerapieInnovative #IT (translated)

The author wrote that the European Congress of Medical Oncology was about to conclude and that he returned convinced that precision oncology was already a reality, no longer a future prospect. He defined the progress made as enormous and concrete and said he was proud of his team's contribution. #ESMO26 https://t.co/tbwkezF4Hi #Oncologia #Medicina #Salute #IT (translated)

The author wrote that the molecular characterization of tumors had revolutionized and continued to transform cancer therapies, arguing that a greater understanding of tumors allowed for the development of better treatments. He added that the data presented that day in Madrid confirmed, in his opinion, that this transformation was unstoppable and relentless, citing #ESMO26. #ESMO26 #Oncologia #RicercaMedica #TerapieInnovative #ES (translated)

The author wrote that from the following week, some “difficult” tumors would be tackled differently thanks to new therapeutic opportunities, which until now were unthinkable. He specified that his statement was based on data that would be presented in the following days, citing ESMO26. (translated)

The author wrote that the next day the European Congress of Medical Oncology would begin in Madrid. He anticipated the presentation of data that, in his opinion, would revolutionize clinical practice for many cancers and reported that thousands of professionals would gather with the common goal of bringing about the long-awaited moment as soon as possible. https://t.co/cP7Us1jJUP #Oncologia #RicercaMedica #CongressoMedico #ES (translated)

The author wrote that the European Congress of Medical Oncology would start in Madrid on October 22. He described the event as an opportunity to directly learn about data that, in his opinion, would once again change clinical practice, and said that participating and contributing to that transformation was a privilege. He added that it was a question of when, not if. #oncologia #congresso #Madrid #ES (translated)

Thanks to this collective effort, the outlook for many metastatic cancers is shifting towards long-term chronicity or, in an increasing number of cases, towards complete remission. It's not about if this will happen, but about when. End. #Salute #Tumori #RicercaMedica #IT (translated)

Serviranno studi clinici rigorosi per provare che questi test migliorano la prognosi dei pazienti trovando un cancro molto prima e contrastando le recidive quando sono all’inizio. Studi che sono giá in corso. Non si tratta di se, ma di quando. Fine. #cancro #ricerca #salute #Nospecificcountriesmentioned.

Questi test potrebbero cambiare il paradigma della oncologia: passeremo dalla cura del tumore sintomatico o visibile, all'eradicazione di poche cellule intercettate nel flusso sanguigno. Meno tossicità dei trattamenti e probabilità di guarigione radicalmente più alte. #oncologia #cura #salute #Nospecificcountrycodescanbeidentifiedintheprovidedtweet.

Misurare l'MRD non è un concetto astratto: in ematologia (es. per leucemie e linfomi) si fa già da anni con successo per guidare le terapie. La vera scommessa scientifica è far entrare questa pratica nella routine clinica anche per i tumori solidi, e succederà, presto. #ematologia #MRD #tumori #IT

Immagina di poter scovare un tumore prima che compaia una massa visibile o che insorgano i primi sintomi. Non è fantascienza, ma la promessa delle biopsie liquide e del sequenziamento del DNA tumorale circolante (ctDNA). Facciamo chiarezza con un thread. #BiopsieLiquide #SequenziamentoDNA #Tumore #IT